Literature DB >> 27805392

Discovery of G Protein-Biased D2 Dopamine Receptor Partial Agonists.

Xin Chen1, John D McCorvy2, Matthew G Fischer1, Kyle V Butler1, Yudao Shen1, Bryan L Roth2, Jian Jin1.   

Abstract

Biased ligands (also known as functionally selective ligands) of G protein-coupled receptors are valuable tools for dissecting the roles of G protein-dependent and independent signaling pathways in health and disease. Biased ligands have also been increasingly pursued by the biomedical community as promising therapeutics with improved efficacy and reduced side effects compared with unbiased ligands. We previously discovered first-in-class β-arrestin-biased agonists of dopamine D2 receptor (D2R) by extensively exploring multiple regions of aripiprazole, a balanced D2R agonist. In our continuing efforts to identify biased agonists of D2R, we unexpectedly discovered a G protein-biased agonist of D2R, compound 1, which is the first G protein-biased D2R agonist from the aripiprazole scaffold. We designed and synthesized novel analogues to explore two regions of 1 and conducted structure-functional selectivity relationship (SFSR) studies. Here we report the discovery of 1, findings from our SFSR studies, and characterization of novel G protein-biased D2R agonists.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27805392      PMCID: PMC5148701          DOI: 10.1021/acs.jmedchem.6b01208

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  48 in total

1.  NMR Chemical Shifts of Common Laboratory Solvents as Trace Impurities.

Authors:  Hugo E. Gottlieb; Vadim Kotlyar; Abraham Nudelman
Journal:  J Org Chem       Date:  1997-10-17       Impact factor: 4.354

2.  Biased ligand quantification in drug discovery: from theory to high throughput screening to identify new biased μ opioid receptor agonists.

Authors:  David Winpenny; Mellissa Clark; Darren Cawkill
Journal:  Br J Pharmacol       Date:  2016-03-01       Impact factor: 8.739

Review 3.  The Akt-GSK-3 signaling cascade in the actions of dopamine.

Authors:  Jean-Martin Beaulieu; Raul R Gainetdinov; Marc G Caron
Journal:  Trends Pharmacol Sci       Date:  2007-03-08       Impact factor: 14.819

4.  Structural determinants of G-protein alpha subunit selectivity by regulator of G-protein signaling 2 (RGS2).

Authors:  Adam J Kimple; Meera Soundararajan; Stephanie Q Hutsell; Annette K Roos; Daniel J Urban; Vincent Setola; Brenda R S Temple; Bryan L Roth; Stefan Knapp; Francis S Willard; David P Siderovski
Journal:  J Biol Chem       Date:  2009-05-28       Impact factor: 5.157

5.  Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics.

Authors:  Bernard Masri; Ali Salahpour; Michael Didriksen; Valentina Ghisi; Jean-Martin Beaulieu; Raul R Gainetdinov; Marc G Caron
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-03       Impact factor: 11.205

Review 6.  Dopamine in schizophrenia: a review and reconceptualization.

Authors:  K L Davis; R S Kahn; G Ko; M Davidson
Journal:  Am J Psychiatry       Date:  1991-11       Impact factor: 18.112

Review 7.  Emerging drugs for schizophrenia: an update.

Authors:  Luisa-Sophie Köster; Maren Carbon; Christoph U Correll
Journal:  Expert Opin Emerg Drugs       Date:  2014-09-19       Impact factor: 4.191

8.  Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase.

Authors:  David M Mottola; Jason D Kilts; Mechelle M Lewis; Hilary S Connery; Q David Walker; Sara R Jones; Raymond G Booth; Deborah K Hyslop; Monford Piercey; R Mark Wightman; Cindy P Lawler; David E Nichols; Richard B Mailman
Journal:  J Pharmacol Exp Ther       Date:  2002-06       Impact factor: 4.030

9.  Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs.

Authors:  Jason D Kilts; Hilary S Connery; Elaine G Arrington; Mechelle M Lewis; Cindy P Lawler; Gerry S Oxford; Karen L O'Malley; Richard D Todd; Bonita L Blake; David E Nichols; Richard B Mailman
Journal:  J Pharmacol Exp Ther       Date:  2002-06       Impact factor: 4.030

10.  Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes.

Authors:  L M Luttrell; S S Ferguson; Y Daaka; W E Miller; S Maudsley; G J Della Rocca; F Lin; H Kawakatsu; K Owada; D K Luttrell; M G Caron; R J Lefkowitz
Journal:  Science       Date:  1999-01-29       Impact factor: 47.728

View more
  18 in total

1.  D2 Dopamine Receptor G Protein-Biased Partial Agonists Based on Cariprazine.

Authors:  Yudao Shen; John D McCorvy; Michael L Martini; Ramona M Rodriguiz; Vladimir M Pogorelov; Karen M Ward; William C Wetsel; Jing Liu; Bryan L Roth; Jian Jin
Journal:  J Med Chem       Date:  2019-04-18       Impact factor: 7.446

Review 2.  Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds.

Authors:  Amy E Moritz; R Benjamin Free; David R Sibley
Journal:  Cell Signal       Date:  2017-07-14       Impact factor: 4.315

3.  In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson's Disease.

Authors:  Agostinho Lemos; Rita Melo; Antonio Jose Preto; Jose Guilherme Almeida; Irina Sousa Moreira; Maria Natalia Dias Soeiro Cordeiro
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

Review 4.  Molecular pharmacology of metabotropic receptors targeted by neuropsychiatric drugs.

Authors:  Bryan L Roth
Journal:  Nat Struct Mol Biol       Date:  2019-07-03       Impact factor: 15.369

5.  Structure-based design of a novel third-generation antipsychotic drug lead with potential antidepressant properties.

Authors:  Zhangcheng Chen; Luyu Fan; Huan Wang; Jing Yu; Dengyu Lu; Jianzhong Qi; Fen Nie; Zhipu Luo; Zhen Liu; Jianjun Cheng; Sheng Wang
Journal:  Nat Neurosci       Date:  2021-12-09       Impact factor: 24.884

6.  Transcriptomic approach predicts a major role for transforming growth factor beta type 1 pathway in L-Dopa-induced dyskinesia in parkinsonian rats.

Authors:  Shetty Ravi Dyavar; Lisa F Potts; Goichi Beck; Bhagya Laxmi Dyavar Shetty; Benton Lawson; Anthony T Podany; Courtney V Fletcher; Rama Rao Amara; Stella M Papa
Journal:  Genes Brain Behav       Date:  2020-09-11       Impact factor: 3.449

7.  A structural basis for how ligand binding site changes can allosterically regulate GPCR signaling and engender functional selectivity.

Authors:  Marta Sanchez-Soto; Ravi Kumar Verma; Blair K A Willette; Elizabeth C Gonye; Annah M Moore; Amy E Moritz; Comfort A Boateng; Hideaki Yano; R Benjamin Free; Lei Shi; David R Sibley
Journal:  Sci Signal       Date:  2020-02-04       Impact factor: 8.192

8.  2016 Philip S. Portoghese Medicinal Chemistry Lectureship: Designing Bivalent or Bitopic Molecules for G-Protein Coupled Receptors. The Whole Is Greater Than the Sum of Its Parts.

Authors:  Amy Hauck Newman; Francisco O Battiti; Alessandro Bonifazi
Journal:  J Med Chem       Date:  2019-09-24       Impact factor: 7.446

9.  Designing Functionally Selective Noncatechol Dopamine D1 Receptor Agonists with Potent In Vivo Antiparkinsonian Activity.

Authors:  Michael L Martini; Caroline Ray; Xufen Yu; Jing Liu; Vladimir M Pogorelov; William C Wetsel; Xi-Ping Huang; John D McCorvy; Marc G Caron; Jian Jin
Journal:  ACS Chem Neurosci       Date:  2019-08-20       Impact factor: 4.418

10.  Ligand-directed bias of G protein signaling at the dopamine D2 receptor.

Authors:  Ee Von Moo; Kasper Harpsøe; Alexander S Hauser; Ikuo Masuho; Hans Bräuner-Osborne; David E Gloriam; Kirill A Martemyanov
Journal:  Cell Chem Biol       Date:  2021-07-23       Impact factor: 8.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.